Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.47 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18065574 | 1.00 | AR (0.47) | ARRORCNR1I2NR1H2NR1H3 | |
| SCHEMBL16328346 | 0.82 | CA1 (0.38) | ARNR1H2NR1H3CA1CA2 | |
| SCHEMBL17026 | 0.82 | AR (0.46) | ARNR1H2NR1H3CA1CA2 | |
| SCHEMBL16799506 | 0.80 | AR (0.47) | ARRORCNR1I2NR1H2NR1H3 | |
| SCHEMBL12329628 | 0.79 | ALDH1A1 (0.47) | ARRORCNR1I2NR1H2NR1H3 | |
| SCHEMBL16363123 | 0.79 | ALDH1A1 (0.47) | ARRORCNR1I2NR1H2NR1H3 | |
| SCHEMBL16098862 | 0.76 | NR1H2 (0.38) | ARNR1I2NR1H2NR1H3CA1 | |
| SCHEMBL18275126 | 0.76 | MEN1 (0.53) | ARRORCNR1I2ALDH1A1TP53 | |
| SCHEMBL7609359 | 0.74 | CYP2A6 (0.38) | ARCA1CA2ALDH1A1TP53 | |
| SCHEMBL1056429 | 0.74 | ALDH1A1 (0.44) | ARALDH1A1TP53TSHRESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-2976341-B1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2976341-B1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| EP-1817276-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-7407959-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-08-05 | — | — | US | disclosed |
| WO-2006056047-A9 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-06-21 | — | — | WO | disclosed |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | AR 2959/4885RORC 236/4885NR1I2 744/4885 |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | JAK1, JAK2, JAK3 | AR 2959/4885RORC 236/4885NR1I2 744/4885 |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | AR 3887/4885RORC 4622/4885NR1I2 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.